Suwipa Ungphaiboon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suwipa Ungphaiboon has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Duangkhae Maneenuan
Drug Delivery System Excellence Center, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla 90110
4 shared publicationsSutasinee Ardhanwanich
2 shared publications- Anunya Suksanga
Research Excellence Center for Innovation and Health Product, Walailak University, Nakhon Si Thammarat, 80160, Thailand, wu.ac.th
1 shared publication - Aornrutai Promsong
Faculty of Medicine, Princess of Naradhiwas University, Narathiwat 96000, Thailand
1 shared publication - Apichat Kaewdech
Prince of Songkla University
1 shared publication - Buncha Ooraikul
Department of Agricultural Food and Nutritional Science, Faculty of Agricultural Life and Environmental Sciences, University of Alberta, Edmonton, AB T6G 2P5, Canada
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Faculty of Medicine Prince of Songkla University in Journal of Health Science and Medical Research
- p. 20261501
Liposomal Delivery of Mangosteen Pericarp Extracts for Enhanced Anti-Aging Activity
Objective: This study aimed to characterize bioactive compounds in mangosteen (Garcinia mangostana L.) pericarp extracts, evaluate their anti-aging–related biological activities, and investigate the potential of liposomal delivery systems for topical applications.Materials and Methods: Crude ethanolic extract and α-mangostin-rich extract were prepared and analyzed for α-mangostin content, total phenolics, and tannins. In vitro antioxidant, anti-tyrosinase, and sunscreen activities were assessed. Liposomal formulations containing the selected extract were prepared and characterized for particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency. The optimized formulation was incorporated into a lotion base and evaluated for anti-aging activity.Results: The crude extract (17.8% α-mangostin) and α-mangostin-rich extract (78.7% α-mangostin) exhibited distinct activity profiles. The α-mangostin-rich extract showed stronger tyrosinase inhibition and greater sunscreen activity but lower antioxidant capacity compared to the crude extract. The optimized liposomal formulation, composed of α-mangostin-rich extract, phosphatidylcholine, and Tween 80 (1:3:0.6, w/w), produced vesicles with a mean particle size of 306.83 ± 1.50 nm, PDI of 0.27 ± 0.01, zeta potential of −38.50 ± 2.49 mV, and entrapment efficiency of 77.6 ± 0.1%. Incorporation of extract-loaded liposomes into lotion significantly enhanced anti‑tyrosinase and sunscreen activities compared with the non-encapsulated extract.Conclusion: α-Mangostin–rich extract demonstrates promising multifunctional anti-aging properties. Liposomal encapsulation improves physicochemical properties and biological activities, supporting its potential application in advanced cosmeceutical formulations.
- 9 November 2026
- Published by Faculty of Medicine Prince of Songkla University in Journal of Health Science and Medical Research
- p. 20261501
Open AccessLiposomal Delivery of Mangosteen Pericarp Extracts for Enhanced Anti-Aging Activity
Objective: This study aimed to characterize bioactive compounds in mangosteen (Garcinia mangostana L.) pericarp extracts, evaluate their anti-aging–related biological activities, and investigate the potential of liposomal delivery systems for topical applications.Materials and Methods: Crude ethanolic extract and α-mangostin-rich extract were prepared and analyzed for α-mangostin content, total phenolics, and tannins. In vitro antioxidant, anti-tyrosinase, and sunscreen activities were assessed. Liposomal formulations containing the selected extract were prepared and characterized for particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency. The optimized formulation was incorporated into a lotion base and evaluated for anti-aging activity.Results: The crude extract (17.8% α-mangostin) and α-mangostin-rich extract (78.7% α-mangostin) exhibited distinct activity profiles. The α-mangostin-rich extract showed stronger tyrosinase inhibition and greater sunscreen activity but lower antioxidant capacity compared to the crude extract. The optimized liposomal formulation, composed of α-mangostin-rich extract, phosphatidylcholine, and Tween 80 (1:3:0.6, w/w), produced vesicles with a mean particle size of 306.83 ± 1.50 nm, PDI of 0.27 ± 0.01, zeta potential of −38.50 ± 2.49 mV, and entrapment efficiency of 77.6 ± 0.1%. Incorporation of extract-loaded liposomes into lotion significantly enhanced anti‑tyrosinase and sunscreen activities compared with the non-encapsulated extract.Conclusion: α-Mangostin–rich extract demonstrates promising multifunctional anti-aging properties. Liposomal encapsulation improves physicochemical properties and biological activities, supporting its potential application in advanced cosmeceutical formulations.
- Open Access
- 27 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6700
Enhanced Oral Delivery of Turmeric Extract via Spray-Dried Microparticles: Biopharmaceutical Performance and In Vitro Microbiota Modulation
To overcome the bioavailability limitations of turmeric, this study developed a spray-dried turmeric extract microparticle (TEM) formulation for improved oral delivery. We investigated its transport, anti-cancer properties, anti-inflammatory effects, and impact on gut microbiota. The TEM formulation successfully improved curcuminoid dissolution by approximately 40-fold and 5-fold compared with unencapsulated extract and curcumin, respectively, and demonstrated effective transepithelial transport. Notably, the TEM formulation showed twofold superior inhibition of gastric cancer cell growth compared to curcumin and significantly suppressed nitric oxide production compared to unencapsulated extract. Furthermore, fecal fermentation studies confirmed that TEMs modulate gut microbiota, with acetate as the predominant metabolite. These findings suggest that TEMs represent a promising standardized approach for managing gastrointestinal diseases.
- 27 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6700
Open AccessEnhanced Oral Delivery of Turmeric Extract via Spray-Dried Microparticles: Biopharmaceutical Performance and In Vitro Microbiota Modulation
To overcome the bioavailability limitations of turmeric, this study developed a spray-dried turmeric extract microparticle (TEM) formulation for improved oral delivery. We investigated its transport, anti-cancer properties, anti-inflammatory effects, and impact on gut microbiota. The TEM formulation successfully improved curcuminoid dissolution by approximately 40-fold and 5-fold compared with unencapsulated extract and curcumin, respectively, and demonstrated effective transepithelial transport. Notably, the TEM formulation showed twofold superior inhibition of gastric cancer cell growth compared to curcumin and significantly suppressed nitric oxide production compared to unencapsulated extract. Furthermore, fecal fermentation studies confirmed that TEMs modulate gut microbiota, with acetate as the predominant metabolite. These findings suggest that TEMs represent a promising standardized approach for managing gastrointestinal diseases.
- Open Access
A Novel Development of a Curcuma aromatica Salisb Extract-Loaded Hydrogel Patch for Acne and Skin Inflammation: Physicochemical Properties and In Vitro Anti-Inflammatory and Anti-Acne Activities
Background/Objectives: Inflammatory skin disorders such as dermatitis, psoriasis, and acne that affect patients’ quality of life and health require safe and effective active delivery systems. In Thai traditional medicine, Curcuma aromatica has long been used to treat skin disorders and for cosmetic skin care. However, the research is scarce. This study aimed to develop and evaluate a novel anti-inflammatory and anti-acne hydrogel patch containing C. aromatica extract. Methods: The hydrogel patch formulations were prepared, and their mechanical properties, in vitro release, skin permeation, in vitro anti-inflammatory and anti-acne activities, and physicochemical properties were studied. Results: The C. aromatica hydrogel patch (CA2 formulation) made from carrageenan, locust bean gum, PVP-K30, and C. aromatica extract displayed excellent physical appearance and mechanical properties; it was smooth, durable, and flexible. Curcumin, an active ingredient, was released from the C. aromatica hydrogel patch within the first 30 min (19.07 ± 1.14%), reaching its peak at 12 h (50.40 ± 3.94%), with sustained permeation of 38.18 ± 0.45% at 24 h. Data from the drug release and permeation study better fit Higuchi’s kinetic model. Additionally, the CA2 hydrogel patch demonstrated anti-inflammatory activity, with an IC50 value of 19.85 ± 0.82 μg/mL, and was also effective against Cutibacterium acne, with an inhibition zone of 12.70 ± 2.10 mm. Conclusions: The developed C. aromatica hydrogel patch not only showed great physicochemical properties but also had anti-inflammatory and anti-acne activities; it prolonged curcumin release, enabling delivery of the drug to treat skin inflammation disorders. The CA hydrogel patch is suitable for use as an anti-acne facial mask and for inflamed skin areas; however, it should be further evaluated in clinical trials.
Open AccessA Novel Development of a Curcuma aromatica Salisb Extract-Loaded Hydrogel Patch for Acne and Skin Inflammation: Physicochemical Properties and In Vitro Anti-Inflammatory and Anti-Acne Activities
Background/Objectives: Inflammatory skin disorders such as dermatitis, psoriasis, and acne that affect patients’ quality of life and health require safe and effective active delivery systems. In Thai traditional medicine, Curcuma aromatica has long been used to treat skin disorders and for cosmetic skin care. However, the research is scarce. This study aimed to develop and evaluate a novel anti-inflammatory and anti-acne hydrogel patch containing C. aromatica extract. Methods: The hydrogel patch formulations were prepared, and their mechanical properties, in vitro release, skin permeation, in vitro anti-inflammatory and anti-acne activities, and physicochemical properties were studied. Results: The C. aromatica hydrogel patch (CA2 formulation) made from carrageenan, locust bean gum, PVP-K30, and C. aromatica extract displayed excellent physical appearance and mechanical properties; it was smooth, durable, and flexible. Curcumin, an active ingredient, was released from the C. aromatica hydrogel patch within the first 30 min (19.07 ± 1.14%), reaching its peak at 12 h (50.40 ± 3.94%), with sustained permeation of 38.18 ± 0.45% at 24 h. Data from the drug release and permeation study better fit Higuchi’s kinetic model. Additionally, the CA2 hydrogel patch demonstrated anti-inflammatory activity, with an IC50 value of 19.85 ± 0.82 μg/mL, and was also effective against Cutibacterium acne, with an inhibition zone of 12.70 ± 2.10 mm. Conclusions: The developed C. aromatica hydrogel patch not only showed great physicochemical properties but also had anti-inflammatory and anti-acne activities; it prolonged curcumin release, enabling delivery of the drug to treat skin inflammation disorders. The CA hydrogel patch is suitable for use as an anti-acne facial mask and for inflamed skin areas; however, it should be further evaluated in clinical trials.
- Open Access
- 10 July 2024
- Published by Pensoft Publishers in Pharmacia
- Vol. 71, 1-10
Spray-dried microparticles of turmeric extract for improved delivery and low toxicity
This study aimed to enhance the delivery of turmeric by encapsulating its extract within microparticles using chitosan and mannitol through the spray drying technique and to assess their acute oral toxicity. The resulting microparticles were spherical, with an average diameter of 4 microns, and comprised 17% curcuminoids and 4% ar-turmerone. In vitro studies demonstrated that these microparticles had a higher release rate of curcuminoids compared to raw turmeric extract and preserved antioxidant activity. In the acute toxicity study, conducted in Wistar rats with a single dose of 2,000 mg/kg, no acute toxic symptoms were observed. According to the Globally Harmonized System of Classification and Labeling of Chemicals, the microparticles were categorized as having relatively low acute toxicity (category 5). These findings support the potential utility of the microparticles in dietary supplements and pharmaceutical applications due to their effective delivery properties and safety profile.
- 10 July 2024
- Published by Pensoft Publishers in Pharmacia
- Vol. 71, 1-10
Open AccessSpray-dried microparticles of turmeric extract for improved delivery and low toxicity
This study aimed to enhance the delivery of turmeric by encapsulating its extract within microparticles using chitosan and mannitol through the spray drying technique and to assess their acute oral toxicity. The resulting microparticles were spherical, with an average diameter of 4 microns, and comprised 17% curcuminoids and 4% ar-turmerone. In vitro studies demonstrated that these microparticles had a higher release rate of curcuminoids compared to raw turmeric extract and preserved antioxidant activity. In the acute toxicity study, conducted in Wistar rats with a single dose of 2,000 mg/kg, no acute toxic symptoms were observed. According to the Globally Harmonized System of Classification and Labeling of Chemicals, the microparticles were categorized as having relatively low acute toxicity (category 5). These findings support the potential utility of the microparticles in dietary supplements and pharmaceutical applications due to their effective delivery properties and safety profile.
- Open Access
- 31 October 2023
- Published by Faculty of Medicine Prince of Songkla University in Journal of Health Science and Medical Research
- p. 20231002
In Vitro Bioactivities of Alcohol-Free Benzydamine Oromucosal Solutions
Objective: This research aimedto evaluate the effects of chitosan and poloxamer 407 on in vitro cytotoxicity, anti-inflammatory, wound healing, and antimicrobial activities of 0.3% w/v benzydamine hydrochloride (HCl) oromucosal solutions.Material and Methods: The effects of three alcohol-free benzydamine HCl oromucosal formulations; containing: 1) 0.5% w/v chitosan, 2) 15% w/v poloxamer 407, and 3) a combination of 0.5% w/v chitosan and 15% w/v poloxamer 407, on in vitro cytotoxicity and biological activities were evaluated and compared to a commercial benzydamine HCl mouth spray, containing alcohol and 0.12% chlorhexidine solution.Results: All alcohol-free benzydamine HCl formulations and their vehicles were less cytotoxic to the macrophage RAW 264.7 cell line than the commercial spray and to the human gingival fibroblast cell line than chlorhexidine, respectively. The formulation containing 0.5% w/v chitosan exhibited the highest wound healing activity on the fibroblast cells among all tested products, and showed anti-inflammatory activity on macrophage cells, which is comparable to benzydamine HCl. Furthermore, from the time-kill assay, this formulation completely inhibited Streptococcus mutans within 1 minute, similar to 0.12% chlorhexidine solution, and reduced the cell number of Candida albicans more rapidly than the commercial spray.Conclusion: The alcohol-free benzydamine HCl solution containing 0.5% w/v chitosan as a mucoadhesive polymer is a promising oral care candidate, which is safe to be used, and has wound healing, anti-inflammatory, and antimicrobial activities.
- 31 October 2023
- Published by Faculty of Medicine Prince of Songkla University in Journal of Health Science and Medical Research
- p. 20231002
Open AccessIn Vitro Bioactivities of Alcohol-Free Benzydamine Oromucosal Solutions
Objective: This research aimedto evaluate the effects of chitosan and poloxamer 407 on in vitro cytotoxicity, anti-inflammatory, wound healing, and antimicrobial activities of 0.3% w/v benzydamine hydrochloride (HCl) oromucosal solutions.Material and Methods: The effects of three alcohol-free benzydamine HCl oromucosal formulations; containing: 1) 0.5% w/v chitosan, 2) 15% w/v poloxamer 407, and 3) a combination of 0.5% w/v chitosan and 15% w/v poloxamer 407, on in vitro cytotoxicity and biological activities were evaluated and compared to a commercial benzydamine HCl mouth spray, containing alcohol and 0.12% chlorhexidine solution.Results: All alcohol-free benzydamine HCl formulations and their vehicles were less cytotoxic to the macrophage RAW 264.7 cell line than the commercial spray and to the human gingival fibroblast cell line than chlorhexidine, respectively. The formulation containing 0.5% w/v chitosan exhibited the highest wound healing activity on the fibroblast cells among all tested products, and showed anti-inflammatory activity on macrophage cells, which is comparable to benzydamine HCl. Furthermore, from the time-kill assay, this formulation completely inhibited Streptococcus mutans within 1 minute, similar to 0.12% chlorhexidine solution, and reduced the cell number of Candida albicans more rapidly than the commercial spray.Conclusion: The alcohol-free benzydamine HCl solution containing 0.5% w/v chitosan as a mucoadhesive polymer is a promising oral care candidate, which is safe to be used, and has wound healing, anti-inflammatory, and antimicrobial activities.
- Open Access
Microbicide Containing Ellagic Acid Can Inhibit HIV-1 Infection
Objectives: Ellagic acid (EA) has a wide range of biological effects. The purpose of this study was to investigate the in vitro effects of EA on HIV-1 replication, viral enzyme activity and cytokine secretion by infected cells. Methods: The anti-HIV-1 activity of EA in solution was determined in vitro using the infection of TZM-bl cells by the nano luciferase-secreting R5-tropic JRCSF strain of HIV-1, which allows for the quantification of viral growth by measuring nano luciferase in the culture supernatants. The effect of EA on the cytokine secretion of TZM-bl cells was determined by a multiplexed bead array after 48 h of HIV-1 exposure. The antiviral effect of EA in the gel formulation (Ellagel), as would be used for vaginal application, was investigated by the inhibition of infection of UC87.CD4.CCR5 cells with R5-tropic pBaLEnv-recombinant HIV-1. Results: EA in solutions of up to 100 µM was not toxic to TZM-bl cells. EA added either 1 h before or 4 h after HIV-1 exposure suppressed the replication of R5-tropic HIV-1 in TZM-bl cells in a dose-dependent manner, with up to 69% inhibition at 50 µM. EA-containing solutions also exhibited a dose-dependent inhibitory effect on HIV-1 replication in U87 cells. When EA was formulated as a gel, Ellagel containing 25 µM and 50 µM EA inhibited HIV-1 replication in U87 cells by 56% and 84%, respectively. In assays of specific HIV-1 enzyme activity, Ellagel inhibited HIV-1 integrase but not protease. EA did not significantly modulate cytokine secretion. Conclusions: We conclude that EA either in solution or in a gel form inhibits HIV infection without adverse effects on target cells. Thus, gel containing EA can be tested as a new microbicide against HIV infection.
Open AccessMicrobicide Containing Ellagic Acid Can Inhibit HIV-1 Infection
Objectives: Ellagic acid (EA) has a wide range of biological effects. The purpose of this study was to investigate the in vitro effects of EA on HIV-1 replication, viral enzyme activity and cytokine secretion by infected cells. Methods: The anti-HIV-1 activity of EA in solution was determined in vitro using the infection of TZM-bl cells by the nano luciferase-secreting R5-tropic JRCSF strain of HIV-1, which allows for the quantification of viral growth by measuring nano luciferase in the culture supernatants. The effect of EA on the cytokine secretion of TZM-bl cells was determined by a multiplexed bead array after 48 h of HIV-1 exposure. The antiviral effect of EA in the gel formulation (Ellagel), as would be used for vaginal application, was investigated by the inhibition of infection of UC87.CD4.CCR5 cells with R5-tropic pBaLEnv-recombinant HIV-1. Results: EA in solutions of up to 100 µM was not toxic to TZM-bl cells. EA added either 1 h before or 4 h after HIV-1 exposure suppressed the replication of R5-tropic HIV-1 in TZM-bl cells in a dose-dependent manner, with up to 69% inhibition at 50 µM. EA-containing solutions also exhibited a dose-dependent inhibitory effect on HIV-1 replication in U87 cells. When EA was formulated as a gel, Ellagel containing 25 µM and 50 µM EA inhibited HIV-1 replication in U87 cells by 56% and 84%, respectively. In assays of specific HIV-1 enzyme activity, Ellagel inhibited HIV-1 integrase but not protease. EA did not significantly modulate cytokine secretion. Conclusions: We conclude that EA either in solution or in a gel form inhibits HIV infection without adverse effects on target cells. Thus, gel containing EA can be tested as a new microbicide against HIV infection.
- 6 October 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (14) , 1919-1931
Efficacy of a Chitosan-curcumin Mixture in Treating Indomethacininduced Acute Gastric Ulcer in Rats
Background: Curcumin is claimed as a potent protectant against Gastric Ulcer (GU) induced by strong necrotizing agents, including NSAIDs through its antioxidant, anti-inflammatory and gastroprotective activities. However, it was found to exert opposite effects to either delay ulcer healing or exacerbate ulcer inflammation through some curative mechanisms differently modified by curcumin dosage. Its ability to inhibit the expression of COX-2 may also delay the healing of NSAIDs-induced GU. Recently, a topical chitosan-curcumin solution has been found to be a safe and potential alternative agent in treating oral ulcer. Therefore, an oral chitosan-curcumin mixture was developed and determined for its efficacy in treating NSAIDs-induced GU in the rat. Methods: A chitosan (150 mg)-curcumin (20 mg) mixture with optimal gastric pH was developed. Indomethacin (30 mg/kg) was given orally to the rat and test preparations were administered orally at 5 h later and then every 24 h for two consecutive days. The sum of all gastric ulcerated areas (mm2) for each stomach was used as ulcer index. Gastric pro-inflammatory mediators and cytoprotective factors were determined. Results: An oral administration of a chitosan-curcumin mixture exerted a superior efficacy than curcumin, chitosan or lansoprazole (a standard antiulcer agent) in healing indomethacin-induced GU. It was revealed that the mixture exhibited the highest anti-oxidant, anti-inflammatory and gastric mucus producing activities including the high potency in down-regulating pro-inflammatory COX-2 and iNOS expression but up-regulating cytoprotective COX-1, nNOS and eNOS expression. Conclusion: The present findings indicated the benefit of a chitosan-curcumin mixture as a potential alternative agent in treating NSAIDs-induced gastric ulcers.
- 6 October 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (14) , 1919-1931
Efficacy of a Chitosan-curcumin Mixture in Treating Indomethacininduced Acute Gastric Ulcer in Rats
Background: Curcumin is claimed as a potent protectant against Gastric Ulcer (GU) induced by strong necrotizing agents, including NSAIDs through its antioxidant, anti-inflammatory and gastroprotective activities. However, it was found to exert opposite effects to either delay ulcer healing or exacerbate ulcer inflammation through some curative mechanisms differently modified by curcumin dosage. Its ability to inhibit the expression of COX-2 may also delay the healing of NSAIDs-induced GU. Recently, a topical chitosan-curcumin solution has been found to be a safe and potential alternative agent in treating oral ulcer. Therefore, an oral chitosan-curcumin mixture was developed and determined for its efficacy in treating NSAIDs-induced GU in the rat. Methods: A chitosan (150 mg)-curcumin (20 mg) mixture with optimal gastric pH was developed. Indomethacin (30 mg/kg) was given orally to the rat and test preparations were administered orally at 5 h later and then every 24 h for two consecutive days. The sum of all gastric ulcerated areas (mm2) for each stomach was used as ulcer index. Gastric pro-inflammatory mediators and cytoprotective factors were determined. Results: An oral administration of a chitosan-curcumin mixture exerted a superior efficacy than curcumin, chitosan or lansoprazole (a standard antiulcer agent) in healing indomethacin-induced GU. It was revealed that the mixture exhibited the highest anti-oxidant, anti-inflammatory and gastric mucus producing activities including the high potency in down-regulating pro-inflammatory COX-2 and iNOS expression but up-regulating cytoprotective COX-1, nNOS and eNOS expression. Conclusion: The present findings indicated the benefit of a chitosan-curcumin mixture as a potential alternative agent in treating NSAIDs-induced gastric ulcers.
- Open Access
- 1 March 2005
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 62 (5) , 485-491
Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus
Purpose. The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Methods. The solubility of triamcinolone acetonide in ethanol, propylene glycol, and glycerin was determined by shaking and equilibrating an excess of triamcinolone acetonide with the solvents for 72 hours. All three solvents were used in formulating a mouthwash. A stock solution of triamcinolone acetonide standard was prepared in ethanol and diluted to yield concentrations of 2, 4, 8, 12, and 16 μg/mL. Analytical sample solutions were prepared by pipetting 0.1 mL of triamcinolone acetonide mouthwash into 10-mL volumetric flasks and diluting to volume with the mobile phase. Accelerated stability studies were conducted by storing the samples in 60-mL amber glass bottles at 45, 60, 70, and 80 °C and 75% relative humidity until the triamcinolone concentration decreased markedly. Efficacy was tested by 20 subjects with a clinical diagnosis of and histologically confirmed symptomatic oral lichen planus who were randomized to use the mouthwash (n = 11) or the commercially available triamcinolone acetonide paste (n = 9). Results. The mouthwash had a satisfactory shelf life and was well accepted by patients. Ten of 11 patients treated with the mouthwash for four weeks reported a positive response, and a complete response in signs and symptoms occurred in 4 and 5 of 11 patients, respectively. No significant difference in clinical improvement was observed between groups. Conclusion. A triamcinolone acetonide mouthwash had a satisfactory shelf life and was well accepted by patients. It did not have a significantly different therapeutic efficacy from the commercial paste dosage form in the treatment of oral lichen planus.
- 1 March 2005
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 62 (5) , 485-491
Open AccessFormulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus
Purpose. The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Methods. The solubility of triamcinolone acetonide in ethanol, propylene glycol, and glycerin was determined by shaking and equilibrating an excess of triamcinolone acetonide with the solvents for 72 hours. All three solvents were used in formulating a mouthwash. A stock solution of triamcinolone acetonide standard was prepared in ethanol and diluted to yield concentrations of 2, 4, 8, 12, and 16 μg/mL. Analytical sample solutions were prepared by pipetting 0.1 mL of triamcinolone acetonide mouthwash into 10-mL volumetric flasks and diluting to volume with the mobile phase. Accelerated stability studies were conducted by storing the samples in 60-mL amber glass bottles at 45, 60, 70, and 80 °C and 75% relative humidity until the triamcinolone concentration decreased markedly. Efficacy was tested by 20 subjects with a clinical diagnosis of and histologically confirmed symptomatic oral lichen planus who were randomized to use the mouthwash (n = 11) or the commercially available triamcinolone acetonide paste (n = 9). Results. The mouthwash had a satisfactory shelf life and was well accepted by patients. Ten of 11 patients treated with the mouthwash for four weeks reported a positive response, and a complete response in signs and symptoms occurred in 4 and 5 of 11 patients, respectively. No significant difference in clinical improvement was observed between groups. Conclusion. A triamcinolone acetonide mouthwash had a satisfactory shelf life and was well accepted by patients. It did not have a significantly different therapeutic efficacy from the commercial paste dosage form in the treatment of oral lichen planus.